Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 53

1.

Initial testing of the hypoxia-activated prodrug PR-104 by the pediatric preclinical testing program.

Houghton PJ, Lock R, Carol H, Morton CL, Phelps D, Gorlick R, Kolb EA, Keir ST, Reynolds CP, Kang MH, Maris JM, Wozniak AW, Gu Y, Wilson WR, Smith MA.

Pediatr Blood Cancer. 2011 Sep;57(3):443-53. doi: 10.1002/pbc.22921. Epub 2010 Dec 27.

2.

Targeting hypoxia in cancer therapy.

Wilson WR, Hay MP.

Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064. Review.

PMID:
21606941
3.

Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells.

Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M, Abeltino M, Ippolito L, Neri A, Ribatti D, Rizzoli V, Martella E, Giuliani N.

Leukemia. 2010 Nov;24(11):1967-70. doi: 10.1038/leu.2010.193. Epub 2010 Sep 2. No abstract available.

PMID:
20811474
4.

Regulation of the HIF-1alpha level is essential for hematopoietic stem cells.

Takubo K, Goda N, Yamada W, Iriuchishima H, Ikeda E, Kubota Y, Shima H, Johnson RS, Hirao A, Suematsu M, Suda T.

Cell Stem Cell. 2010 Sep 3;7(3):391-402. doi: 10.1016/j.stem.2010.06.020.

5.

The distinct metabolic profile of hematopoietic stem cells reflects their location in a hypoxic niche.

Simsek T, Kocabas F, Zheng J, Deberardinis RJ, Mahmoud AI, Olson EN, Schneider JW, Zhang CC, Sadek HA.

Cell Stem Cell. 2010 Sep 3;7(3):380-90. doi: 10.1016/j.stem.2010.07.011.

6.

Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug.

Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I, Liu Q, Sun JD, Van Camp B, Hart CP, Vanderkerken K.

Blood. 2010 Sep 2;116(9):1524-7. doi: 10.1182/blood-2010-02-269126. Epub 2010 Jun 7.

7.

HIF-1 and HIF-2 transcription factors--similar but not identical.

Loboda A, Jozkowicz A, Dulak J.

Mol Cells. 2010 May;29(5):435-42. doi: 10.1007/s10059-010-0067-2. Epub 2010 Apr 12. Review.

8.

Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches.

Winkler IG, Barbier V, Wadley R, Zannettino AC, Williams S, Lévesque JP.

Blood. 2010 Jul 22;116(3):375-85. doi: 10.1182/blood-2009-07-233437. Epub 2010 Apr 14.

9.

Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway.

Sung B, Ahn KS, Aggarwal BB.

Cancer Res. 2010 Apr 15;70(8):3259-68. doi: 10.1158/0008-5472.CAN-09-4230. Epub 2010 Mar 30.

10.

Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.

Jin Y, Lu Z, Ding K, Li J, Du X, Chen C, Sun X, Wu Y, Zhou J, Pan J.

Cancer Res. 2010 Mar 15;70(6):2516-27. doi: 10.1158/0008-5472.CAN-09-3950. Epub 2010 Mar 9.

11.

Impact of interactions of cellular components of the bone marrow microenvironment on hematopoietic stem and progenitor cell function.

Chitteti BR, Cheng YH, Poteat B, Rodriguez-Rodriguez S, Goebel WS, Carlesso N, Kacena MA, Srour EF.

Blood. 2010 Apr 22;115(16):3239-48. doi: 10.1182/blood-2009-09-246173. Epub 2010 Feb 12.

12.

The bioreductive prodrug PR-104A is activated under aerobic conditions by human aldo-keto reductase 1C3.

Guise CP, Abbattista MR, Singleton RS, Holford SD, Connolly J, Dachs GU, Fox SB, Pollock R, Harvey J, Guilford P, Doñate F, Wilson WR, Patterson AV.

Cancer Res. 2010 Feb 15;70(4):1573-84. doi: 10.1158/0008-5472.CAN-09-3237. Epub 2010 Feb 9.

13.

Nuclear factor-kappaB signaling: a contributor in leukemogenesis and a target for pharmacological intervention in human acute myelogenous leukemia.

Reikvam H, Olsnes AM, Gjertsen BT, Ersvar E, Bruserud Ø.

Crit Rev Oncog. 2009;15(1-2):1-41. Review.

PMID:
20136626
14.

NF-kappaB activation mediates resistance to IFN beta in MLL-rearranged acute lymphoblastic leukemia.

Tracey L, Streck CJ, Du Z, Williams RF, Pfeffer LM, Nathwani AC, Davidoff AM.

Leukemia. 2010 Apr;24(4):806-12. doi: 10.1038/leu.2010.2. Epub 2010 Feb 4.

15.

A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors.

Jameson MB, Rischin D, Pegram M, Gutheil J, Patterson AV, Denny WA, Wilson WR.

Cancer Chemother Pharmacol. 2010 Mar;65(4):791-801. doi: 10.1007/s00280-009-1188-1. Epub 2009 Dec 10.

PMID:
20012293
16.

Human cancers converge at the HIF-2alpha oncogenic axis.

Franovic A, Holterman CE, Payette J, Lee S.

Proc Natl Acad Sci U S A. 2009 Dec 15;106(50):21306-11. doi: 10.1073/pnas.0906432106. Epub 2009 Dec 2.

17.

Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.

Semenza GL.

Oncogene. 2010 Feb 4;29(5):625-34. doi: 10.1038/onc.2009.441. Epub 2009 Nov 30. Review.

18.

The role of NF-kappaB in hypoxia-induced gene expression.

Taylor CT, Cummins EP.

Ann N Y Acad Sci. 2009 Oct;1177:178-84. doi: 10.1111/j.1749-6632.2009.05024.x. Review.

PMID:
19845620
19.

HIF-2alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells.

Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjölund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S, Cammenga J, Fredlund E, Kaplan DR, Påhlman S.

Proc Natl Acad Sci U S A. 2009 Sep 29;106(39):16805-10. doi: 10.1073/pnas.0904606106. Epub 2009 Sep 16.

20.

Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia.

Kizaka-Kondoh S, Konse-Nagasawa H.

Cancer Sci. 2009 Aug;100(8):1366-73. doi: 10.1111/j.1349-7006.2009.01195.x. Epub 2009 May 14. Review.

Supplemental Content

Support Center